Clinical Trial Update: Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing dose-adjusted adjuvant FEC to standard FEC for breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FEC (fluorouracil, epirubicin, cyclophosphamide)

Snippet

Sponsor: Henrik Lindman | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED